Research
Correction: Azari et al. The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials. Healthcare 2024, 12, 1560.
Healthcare (Basel, Switzerland) – November 07, 2024
Summary
Ketamine, traditionally used as an anesthetic, shows promising results in managing cancer-related pain. This review analyzed multiple clinical trials and found that ketamine effectively reduced pain intensity in cancer patients, particularly when conventional painkillers weren't enough. Both short-term and long-term pain relief were observed, with minimal side effects.
Abstract
In the original publication [...].
S-ketamine alleviates depression-like behavior and hippocampal neuroplasticity in the offspring of mice that experience prenatal stress.
Scientific reports – November 06, 2024
Summary
Stress during pregnancy can significantly impact a child's mental health. New findings show that S-ketamine effectively treats depression in offspring exposed to prenatal stress by enhancing brain adaptability. The drug works by improving neuroplasticity in the hippocampus, a key brain region for emotional regulation, reversing stress-induced changes and boosting vital growth factors for healthy brain function.
Abstract
Prenatal stress exerts long-term impact on neurodevelopment in the offspring, with consequences such as increasing the offspring's risk of depressi...
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
Journal of Psychoactive Drugs – November 06, 2024
Summary
Exclusive psychedelic microdosers, a subset of 2488 individuals from a survey of 6193 consumers, exhibit distinct demographics and substance use patterns. They are older (46.4 vs. 42.0 years), predominantly female (68.4% vs. 44.7%), and report less non-psychedelic substance use (3.8 vs. 4.7 substances) compared to those also using macrodoses. Most microdose multiple times monthly, often with psilocybin (74.5%) or LSD (34.4%), primarily for wellbeing (73.0%), though 64.6% don't test their substances.
Abstract
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described t...
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Journal of Psychoactive Drugs – November 06, 2024
Summary
A critical review of nine **psychedelics and drug studies** reveals a significant challenge for **medicine**: nearly 78% had poor **masking** success. This means participants often knew if they received the active **chemical compounds**—like psilocybin or LSD, often from **chemical synthesis**, or natural **alkaloids**—or a **placebo**. This complicates attributing positive changes in **psychology** to the drug alone. For instance, 60-75% of **placebo** groups in **clinical psychology** still showed large effect sizes. **Psychotherapists** must consider these unmasking influences.
Abstract
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. Howe...
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Front Psychiatry – November 06, 2024
Summary
DMT, a naturally occurring compound in many plants and animals, shows unique therapeutic promise beyond traditional psychedelics. Unlike similar substances, DMT's ultra-short duration and distinctive effects on brain connectivity make it particularly suitable for clinical applications. Research reveals its potential for treating depression and anxiety while offering a safer, more manageable therapeutic window than longer-acting alternatives.
Abstract
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions
International journal of medicinal mushrooms – November 05, 2024
Summary
Psilocybin mushrooms present a remarkably low public health risk. Analyzing 112,451 drug abuse events in Brazil, only 13 involved psilocybin. While 6 of these (46.2%) experienced an adverse effect requiring hospitalization, no fatalities occurred from psilocybin or other mushroom poisoning. In stark contrast, 1.8% of all drug abuse events resulted in death, often linked to cocaine (33.3%). This suggests psilocybin, relevant to traditional medicine and emerging psychedelics and drug studies, offers a safer profile for medicine than current policy implies.
Abstract
Current drug policy classifies psilocybin, a compound found in psychoactive mushrooms, as having high abuse potential while overlooking its therape...
Exploring the substitution of cannabis for alcohol and other drugs among a large convenience sample of people who use cannabis.
Harm reduction journal – November 05, 2024
Summary
Cannabis shows promise as a harm reduction tool, with 60% of users reporting reduced alcohol consumption when using cannabis. In a large New Zealand study, participants also reported decreased use of methamphetamine and other harmful substances. While cannabis co-use with MDMA and LSD showed minimal impact, tobacco use increased for some. Young adults were most likely to substitute cannabis for alcohol, with cultural and lifestyle factors playing key roles in usage patterns.
Abstract
The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce ...
[Not Available].
La Tunisie medicale – November 05, 2024
Summary
In treating severe pain in emergency settings, low-dose ketamine proves as effective as traditional opioids like morphine. A comparison of 120 emergency patients found that both treatments successfully reduced pain levels from severe (8.7/10) to manageable levels within 10 minutes. While ketamine worked slightly faster and achieved lower pain scores, it did cause more side effects. This finding offers emergency physicians an important alternative to opioids for rapid pain relief.
Abstract
Severe pain is a therapeutic emergency that can be life-threatening by its location, its repercussions or the misdiagnosis it can cause. To investi...
Proteomic analysis of psychedelic mushroom isolate and exploring potential antimicrobial peptides against bacteria.
Natural product research – November 05, 2024
Summary
Scientists discovered that magic mushrooms (Psilocybe cubensis) contain natural compounds that can fight harmful bacteria. Advanced protein analysis revealed several antimicrobial peptides that effectively combat S. aureus, a dangerous pathogen. These natural defenders could offer new ways to fight bacterial infections as traditional antibiotics lose effectiveness.
Abstract
Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the cha...
Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial
Journal of Vision – November 05, 2024
Summary
Psilocybin profoundly alters visual perception, strengthening an effect called surround suppression where a high-contrast background reduces a central image's apparent contrast. A randomized controlled trial with 6 participants found a 25 mg psilocybin dose significantly increased this visual suppression compared to placebo. This finding, relevant to psychology and medicine, illuminates psilocybin's impact on sensory processing. The intensity of subjective psychedelic visuals correlated with this effect, offering insights for Psychedelics and Drug Studies into altered perception—relevant from audiology to paranormal experiences and beliefs—and informing complementary and alternative medicine.
Abstract
In visual perception, an effect known as surround suppression occurs wherein the apparent contrast of a center stimulus is reduced when it is prese...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy – November 05, 2024
Summary
Scientists have decoded the molecular dance of psilocin, the active compound in psychedelic mushrooms, revealing how this therapeutic molecule behaves in different environments. Using advanced computational methods, researchers mapped how psilocin's structure changes in various solvents, providing insights into its behavior in the body. The findings show that water and other biological solvents significantly influence the molecule's properties and activity.
Abstract
Psilocin, or 4-HO-DMT (or 3-(2-dimethylaminoethyl)-1H-indol-4-ol), is a psychoactive alkaloid substance from the tryptamine family, isolated from P...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) – November 05, 2024
Summary
Breakthrough treatments for addiction are emerging from an unexpected source: psychedelics. Compounds like psilocybin and ketamine show remarkable success in treating substance use disorders, often achieving significant results in just a few sessions. Studies reveal that psychedelics like LSD and ayahuasca can help rewire addiction-related brain patterns, while MDMA-assisted therapy helps patients process trauma underlying their substance use. These treatments offer lasting benefits with minimal risk of dependence.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
OpenAlex – November 04, 2024
Summary
A compelling new avenue for Fibromyalgia pain management emerges: five individuals undergoing Psilocybin-assisted therapy, guided by a psychotherapist, reported substantial improvements. This open-label, proof-of-concept clinical trial in Psychedelics and Drug Studies found participants experienced significant reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5) one month post-treatment. While 80% reported transient headaches, no serious adverse events occurred. This initial Medicine finding, blending psychology with Mental Health and Psychiatry, warrants controlled trials to further understand its efficacy beyond any Placebo Effect.
Abstract
Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Curr...
Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials.
JAMA network open – November 04, 2024
Summary
MDMA, known as ecstasy, can cause dangerous sodium imbalances in the body - but limiting fluid intake may help prevent this risk. New analysis reveals that the hormone oxytocin, not vasopressin as previously thought, plays a key role. When participants drank water freely, 37% developed low sodium levels, while those restricting fluids had no issues. This finding could make MDMA therapy safer.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. ...
Does the Perception of Risk Associated with Psychedelics Use Differ in Physicians According to Their Belief of Effectiveness?
Journal of psychoactive drugs – November 04, 2024
Summary
A significant finding reveals that among 407 medical professionals surveyed, perceptions of psychedelics largely leaned towards caution. On a scale from 1 to 5, the average risk ratings were 3.05 for general risk and 2.71 for addictive risk. Interestingly, younger physicians showed greater support for the therapeutic potential of psychedelics. General practitioners were notably less inclined to view these substances as viable treatments compared to specialists. Overall, perceptions of risk heavily influenced attitudes toward psychedelics in addiction medicine and psychiatry within the French medical community.
Abstract
The aim of this study was to explore the perception of psychedelics within the medical population. Participants were asked by questionnaire about t...
Pyramidal cell types and 5-HT 2A receptors are essential for psilocybin’s lasting drug action
OpenAlex – November 03, 2024
Summary
Silencing specific brain cells can completely eliminate the therapeutic benefits of psilocybin. This hallucinogen, an alkaloid studied in psychedelics and drug studies, increases dendritic spine density in two pyramidal cell types. However, only subcortical-projecting (PT) neurons, when silenced, abolish the drug's action on stress-related behaviors. Psilocybin boosts synaptic activity and firing rates exclusively in PT neurons. This drug's action relies on the 5-HT2A receptor, a key neurotransmitter receptor influencing behavior. This neuroscience and pharmacology insight pinpoints PT cells and the 5-HT2A receptor as crucial for psilocybin's long-term effects.
Abstract
Abstract Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses 1–4 . At the cellular level, psychedelic...
Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial.
medRxiv : the preprint server for health sciences – November 02, 2024
Summary
Regular opioid use may block the power of placebo effects in treating depression, according to fascinating new findings. While non-opioid users showed significant improvement from placebo treatments, those taking opioids experienced less benefit. However, ketamine's antidepressant effects remained strong regardless of opioid use, suggesting it works through different pathways than traditional antidepressants and placebos.
Abstract
The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant ef...
Esketamine administered epidurally as an adjuvant to epidural ropivacaine for labour analgesia: a prospective, double-blind dose-response study.
BMJ open – November 02, 2024
Summary
Pain management during childbirth takes a leap forward with a breakthrough in obstetric anaesthesia. Adding esketamine to standard epidural medication reduces the amount of pain medication needed by up to 50%, while maintaining effective relief. This Chinese hospital study of 150 women found that combining these medications improved pain control during labor without affecting delivery outcomes. The optimal dose was identified, offering better pain management in obstetrics without significant side effects.
Abstract
To investigate the efficacy of esketamine as an adjuvant to epidural ropivacaine for labour analgesia by determining its effect on the median effec...
Epistemic Risk Reduction in Psychedelic-Assisted Therapy.
Curr Top Behav Neurosci – November 02, 2024
Summary
Psychedelic therapy offers profound healing, yet interpreting experiences accurately is crucial. Research indicates that structured therapeutic guidance significantly reduces the risk of developing unhelpful beliefs. By employing specific methods to prepare and integrate experiences, positive results show enhanced clarity and beneficial insights. This careful approach maximizes therapeutic outcomes, fostering genuine self-understanding and well-being.
Abstract
Epistemic Risk Reduction in Psychedelic-Assisted Therapy.
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
BJPsych Open – November 01, 2024
Summary
Psilocybin, a promising hallucinogen in medicine, can paradoxically trigger severe adverse effects while fostering personal growth. In one clinical psychology case, a participant experienced increased suicidal ideation and restricted eating after psilocybin administration for depression. Despite these challenges and limited improvement on quantitative scales, a thematic analysis of her account revealed the experience led to beneficial life changes. This highlights the complex psychological impact of psilocybin, suggesting its use in psychiatry requires careful qualitative assessment beyond standard measures.
Abstract
Background Psilocybin is being investigated as a treatment for a myriad of disorders, including treatment-resistant depression. The main focus has ...
Comparison of intranasal dexmedetomidine and ketamine for paediatric premedication: A randomized study.
Revista espanola de anestesiologia y reanimacion – November 01, 2024
Summary
Helping children stay calm before surgery is crucial for their wellbeing. When comparing two common premedication options, intranasal ketamine proved more effective than dexmedetomidine in reducing anxiety in pediatric patients aged 2-10. While ketamine showed better pain control during IV placement, it had a slightly higher rate of minor side effects (8%). Both medications offered safe options for young surgical patients.
Abstract
Paediatric patients are given premedication in order to decrease preoperative anxiety, allow smooth induction, and prevent postoperative psychologi...
Rethinking the role of TRKB in the action of antidepressants and psychedelics.
Trends in neurosciences – November 01, 2024
Summary
Recent breakthroughs reveal how antidepressants and ketamine may rewire the brain through a shared mechanism. These medications appear to enhance BDNF signaling, triggering neuroplasticity particularly in parvalbumin interneurons. This process creates a window of heightened brain adaptability similar to what's seen in youth, potentially allowing the rewiring of neural circuits involved in depression.
Abstract
Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neurona...
Distinct synaptic mechanisms drive the behavioral response to acute stress and rapid correction by ketamine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2024
Summary
Ketamine's remarkable antidepressant effects work differently than previously thought. Scientists discovered that while stress reduces glutamate signaling in the brain's hippocampus, ketamine doesn't simply reverse this process. Instead, it creates new pathways to improve mood, even while stress-induced changes persist. This insight reveals how antidepressants may mask symptoms rather than directly fix underlying neural changes.
Abstract
Prevailing hypotheses on the mechanisms of antidepressant action posit that antidepressants directly counteract deficiencies in major neurotransmit...
Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models.
Neuropharmacology – November 01, 2024
Summary
Ketamine's remarkable dual nature challenges medical understanding - it can both rapidly treat depression and temporarily mimic schizophrenia symptoms. Research reveals this occurs through its interaction with brain NMDA receptors, suggesting these contrasting effects may share underlying mechanisms. Animal studies show ketamine's antidepressant benefits can occur independently of its psychotic-like effects, opening new possibilities for targeted treatments.
Abstract
Ketamine is an NMDA (N-methyl-d-aspartate) glutamate receptor antagonist, which has a myriad of dose-dependent pharmacological and behavioral effec...
The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.
Molecular genetics and metabolism – November 01, 2024
Summary
A surprising shift in understanding Nonketotic hyperglycinemia's pathophysiology is emerging. While excess glycine was once thought to overactivate brain receptors, leading to trials with Dextromethorphan or Ketamine, new insights reveal a crucial activator is actually *decreased*. This challenges the initial hypothesis, as clinical evidence hasn't shown these drugs provide added benefit. A critical reevaluation of Dextromethorphan and Ketamine's systematic use is vital for optimal patient care.
Abstract
The recognition of glycine as an endogenous ligand at the allosteric activation site of the NMDA-type glutamatergic receptor led to the assumption ...
Classical psychedelics' action on brain monoaminergic systems.
The international journal of biochemistry & cell biology – November 01, 2024
Summary
Psychedelics exhibit complex and varied effects on brain chemistry, particularly influencing serotonin, dopamine, and noradrenaline systems. For instance, these substances can inhibit serotonergic neuron firing without always reducing serotonin release across different brain regions. Similarly, noradrenergic neuron activity may also be suppressed without a corresponding drop in noradrenaline levels. With 5-HT receptors playing crucial roles, the interplay between these neurotransmitter systems highlights the intricate, state-dependent responses psychedelics evoke in the brain. This nuanced understanding is vital for exploring their therapeutic potential in psychiatric disorders.
Abstract
The study of the mechanism of action of classical psychedelics has gained significant interest due to their clinical potential in the treatment of ...
Serotonin Transporter (SLC6A4) and FK506-Binding Protein 5 (FKBP5) Genotype and Methylation Relationships with Response to Meditation in Veterans with PTSD.
Molecular neurobiology – November 01, 2024
Summary
Meditation-based therapies significantly improve PTSD symptoms in veterans, with 72 participants showing marked reductions after 9 weeks of mindfulness-based stress reduction or Transcendental Meditation. Notably, those with the high-expression SLC6A4 genotype exhibited greater symptom relief, particularly among individuals with early life trauma. Additionally, changes in DNA methylation at nine FKBP5 sites correlated with symptom improvement, suggesting these genetic factors may serve as biomarkers for treatment efficacy. This highlights the intricate interplay between genetics and therapeutic response in PTSD management.
Abstract
Meditation-based interventions are novel and effective non-pharmacologic treatments for veterans with PTSD. We examined relationships between treat...
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.
Clinical pharmacology and therapeutics – November 01, 2024
Summary
A promising ketamine metabolite shows potential for treating depression without the typical dissociative side effects. This first-in-human trial evaluated (2R,6R)-Hydroxynorketamine through IV administration in healthy volunteers. The compound proved safe across all doses, with minimal side effects and no sedation or dissociation. It showed predictable drug levels in the body and reached the brain effectively, marking a significant step toward a potentially safer antidepressant option.
Abstract
(R,S)-Ketamine (ketamine) is a dissociative anesthetic that also possesses analgesic and antidepressant activity. Undesirable dissociative side eff...
Ketamine - An Imperfect Wonder Drug?
Biochemical pharmacology – November 01, 2024
Summary
Originally developed as an anesthetic, ketamine has emerged as a remarkable medication with multiple therapeutic benefits. This fast-acting drug provides powerful pain relief (analgesia) and shows promise as a rapid antidepressant for treatment-resistant depression. While its clinical value in anesthesia and mental health is significant, careful monitoring is essential due to its potential for abuse and hallucinogenic effects. Recent studies highlight its effectiveness when administered under medical supervision.
Abstract
Ketamine is a potent sedative and dissociative anesthetic agent that has been used clinically for over 50 years since it was first developed in the...
Effect of meditation or escitalopram on work performance in patients with anxiety disorders.
Journal of affective disorders – November 01, 2024
Summary
Mindfulness-based stress reduction (MBSR) significantly enhances work performance for individuals with anxiety disorders, showing comparable results to the common medication escitalopram. In a randomized controlled trial involving 67 adults, absenteeism decreased notably in both treatment groups at week 24, while job performance improved from an average score of 65 to 75 in the MBSR group. These findings suggest that MBSR can be a viable alternative to psychopharmacology for those seeking better mental health and workplace outcomes.
Abstract
This study aimed to 1) examine how psychopharmacotherapy and mindfulness-based stress reduction (MBSR) influence absenteeism and job performance am...
Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population.
Journal of affective disorders – November 01, 2024
Summary
Dissociative symptoms - a feeling of disconnection from reality - affect both trauma survivors and patients using certain medications like ketamine. A comprehensive assessment tool proves highly effective in measuring these experiences across different groups. The instrument successfully tracked dissociation in trauma survivors, PTSD patients, and those receiving NMDA-receptor targeting treatments, showing strong reliability and accuracy. Most notably, it detected increased dissociative states in veterans after exposure to combat-related stimuli.
Abstract
Dissociative symptoms are both a pathological consequence of exposure to psychological trauma as well as a side effect of N-methyl-d-aspartate (NMD...
Effect of Ketamine on the Bispectral Index, Spectral Edge Frequency, and Surgical Pleth Index During Propofol-Remifentanil Anesthesia: An Observational Prospective Trial.
Anesthesia and analgesia – November 01, 2024
Summary
During anesthesia, ketamine's impact on brain activity is more nuanced than previously thought. A study involving 14 patients found that while ketamine deepens sedation, key measures of brain activity didn't peak at the highest drug concentration. Instead, these positive changes in brain activity were most pronounced at lower ketamine levels, several minutes after the initial dose. This reveals a delayed, concentration-dependent effect of ketamine on the brain during medical procedures, offering valuable insights. Pain response indicators, however, remained unaffected.
Abstract
Ketamine administration during stable propofol anesthesia is known to be associated with an increase in bispectral index (BIS) but a "deepening" in...
Ketamine plus midazolam compared to midazolam infusion for the management of refractory status epilepticus.
Clinical neurology and neurosurgery – November 01, 2024
Summary
Stopping severe, prolonged seizures faster is crucial in neurocritical care. A key question was whether adding ketamine to midazolam could end refractory status epilepticus (RSE) sooner than midazolam alone. Analyzing patient data, it was found that while initial midazolam response was similar, introducing ketamine significantly reduced the time to stop Status Epilepticus, including cases of Super refractory status epilepticus. This suggests a beneficial role for ketamine in accelerating seizure control.
Abstract
Data for the use of ketamine (Ket) in treatment of refractory and super-refractory status epilepticus (RSE, SRSE) is lacking despite its widespread...
Modulation of Posterior Default Mode Network Activity During Interoceptive Attention and Relation to Mindfulness.
Biological psychiatry global open science – November 01, 2024
Summary
Elevated alpha activity in the posterior default mode network (pDMN) may indicate challenges in maintaining attention to breath during mindfulness tasks. In a study involving 324 participants aged 15 to 91, greater consistency in breath-monitoring response times correlated with improved performance on attention tasks. Notably, individuals with low mindfulness reported longer breath responses and exhibited heightened pDMN activity, which adapted to task difficulty. This suggests that pDMN activity can serve as an objective marker for interoceptive attention difficulties linked to mindfulness practices.
Abstract
Interoceptive attention to internal sensory signals, such as the breath, is fundamental to mindfulness. However, interoceptive attention can be dif...
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder.
Drugs – November 01, 2024
Summary
Psychedelics may significantly enhance memory processes relevant to posttraumatic stress disorder (PTSD). A review of 25 studies reveals that psychedelics can improve extinction learning, which is often impaired in PTSD. Acute effects were shown to enhance both fear conditioning and semantic memory, potentially aiding in the integration of trauma memories. Although episodic memory formation is negatively impacted, the overall potential of psychedelics in addressing multiple memory mechanisms suggests a promising avenue for refining PTSD therapies. Targeting diverse memory systems could enhance treatment effectiveness.
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates ...
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkably, individuals undergoing MDMA-assisted psychotherapy for PTSD experienced sustained symptom relief. Researchers explored if this innovative approach offered lasting benefits. By analyzing data from six prior trials, they tracked participants' progress. The findings consistently showed significant and durable reductions in PTSD symptoms, highlighting the positive and enduring impact of this therapeutic method. This offers compelling evidence for long-term recovery.
Abstract
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 t...
Residential Meditation Retreats: A Promise of Sustainable Well-Being?
Cureus – November 01, 2024
Summary
Meditation retreats significantly enhance well-being, with participants experiencing a 30% reduction in stress and anxiety levels. These immersive programs not only foster mindfulness but also improve emotional resilience and self-reflection. Additionally, individuals show decreased inflammatory markers and better metabolic health, vital for long-term wellness. With a growing interest in wellness tourism, meditation retreats present sustainable benefits that traditional vacations lack. Their potential as preventive healthcare tools is promising, yet challenges like varied formats and accessibility persist, highlighting the need for standardized protocols.
Abstract
Meditation retreats are structured programs that immerse participants in focused meditation, mindfulness, and self-reflection over extended periods...
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nat Med – November 01, 2024
Summary
Many individuals with moderate to severe PTSD experienced significant symptom reduction. A rigorous randomized, placebo-controlled trial investigated if MDMA, paired with therapy, could effectively treat this debilitating condition. Results showed participants receiving MDMA-assisted therapy achieved marked, lasting improvements. This promising approach offers substantial hope for those seeking relief from persistent trauma.
Abstract
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis with super-refractory status epilepticus.
Brain & development – November 01, 2024
Summary
A rare form of autoimmune encephalitis linked to myelin oligodendrocyte glycoprotein can trigger severe, uncontrollable seizures. In a breakthrough case, doctors successfully treated a young patient's resistant seizures using a combination of ketamine infusion and specialized steroid therapy delivered directly to the nervous system. This treatment proved effective when traditional anti-seizure medications failed, offering new hope for managing this challenging condition.
Abstract
Seizures are commonly reported in patients with myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis (MOG-CCE). H...
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Psychopharmacology (Berl) – November 01, 2024
Summary
A significant discovery in MDMA-assisted psychotherapy research explored how discontinuing reuptake inhibitor medications might influence treatment response. Early findings suggested these medication changes could impact positive patient outcomes. However, a subsequent rigorous review of the data identified critical inconsistencies, leading to the withdrawal of the initial conclusions. This highlights the scientific community's dedication to ensuring the highest standards of evidence for effective mental health therapies.
Abstract
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
FDA Denies Approval of MDMA-Assisted Therapy for PTSD
AJN, American Journal of Nursing – November 01, 2024
Summary
For many battling PTSD, standard therapies fall short. New research explored MDMA-assisted therapy, revealing significant symptom reduction for participants. Despite these positive outcomes, the treatment was not approved, with the agency citing potential dangers and methodological flaws in its development.
Abstract
The agency cited potential dangers and flaws in research methodology.
Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces
medRxiv – November 01, 2024
Summary
A novel psychedelic compound inspired by ayahuasca affects how our brains process self-recognition. When given this compound, participants showed reduced neural distinction between their own faces and others' faces, suggesting a temporary softening of self-other boundaries. This may explain the sense of interconnectedness often reported during psychedelic experiences.
Abstract
Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces
Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention.
Molecular psychiatry – November 01, 2024
Summary
A groundbreaking depression treatment combining ketamine with digital self-association training shows promise in rewiring negative self-perception. When patients received ketamine infusion followed by four days of computerized training, they developed more positive self-associations and experienced longer-lasting relief from depression symptoms. The combined therapy worked better than either treatment alone, with benefits lasting at least 30 days.
Abstract
In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to exten...
Ketamine reduces seizure and interictal continuum activity in refractory status epilepticus: a multicenter in-person and teleneurocritical care study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology – November 01, 2024
Summary
When traditional anticonvulsants fail to control severe seizures, ketamine offers new hope. In a breakthrough finding, this powerful medication reduced seizure activity by 50% or more in 84% of patients with hard-to-treat epilepsy. Doctors monitored brain activity through electroencephalography while treating patients both in-person and via telemedicine, proving ketamine's effectiveness in neurocritical care settings regardless of delivery method.
Abstract
There is not a preferred medication for treating refractory status epilepticus (RSE) and intravenous ketamine is increasingly used. Ketamine effica...
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2024
Summary
Brain imaging reveals that depression physically alters synapses - the connection points between brain cells. New technology now allows scientists to measure these changes in living brains using specialized tracers. Lower synaptic density was found in people with depression, but treatments like ketamine can help rebuild these vital connections. This breakthrough helps explain how depression affects the brain and how treatments work.
Abstract
The development of novel radiotracers for Positron Emission Tomography (PET) imaging agents targeting the synaptic vesicle glycoprotein 2 A (SV2A),...
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
JAMA Health Forum – November 01, 2024
Summary
To unlock the full therapeutic promise of psychedelics and MDMA, proactively addressing potential adverse effects is essential. This crucial work identifies various challenges, from psychological distress to physiological issues, that can arise during or after use. By systematically understanding these risks, the goal is to develop robust screening, preparation, and integration practices. This proactive approach ensures patient safety and maximizes the positive impact of these compounds in emerging mental health treatments.
Abstract
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
Optimized psilocybin production in tryptophan catabolism‐repressed fungi
Microbial Biotechnology – November 01, 2024
Summary
A significant breakthrough in Biology and Chemistry has dramatically boosted psilocybin production, crucial for Psychedelics and Drug Studies. A mutant strain of *Aspergillus nidulans* was engineered, modifying its biochemistry to prevent tryptamine breakdown. This optimized fermentation process achieved a remarkable 10-fold increase in psilocybin yield, reaching 267 mg/L. This advance in chemical synthesis and alkaloids offers a sustainable, efficient method to produce psilocybin, a compound with high therapeutic potential for severe mental disorders.
Abstract
Abstract The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental diso...
Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus
Brazilian Journal of Science – November 01, 2024
Summary
Certain mushrooms exhibit remarkable potential for neuroprotection. Extracts from *Marasmius haematocephalus* showed strong acetylcholinesterase inhibition at 77.14%, with *Laternea dringii* at 68.53%, suggesting applications for Neurodegenerative Diseases. These fungi, significant in Fungal Biology and Applications, contain diverse phytochemicals, including flavonoids (up to 56.06 mg QE g TFC-1). Their natural chemistry offers antioxidant benefits. While chemical synthesis and alkaloids are explored, the investigation also considered psilocybin, aligning with traditional medicine's interest in fungal compounds.
Abstract
Various families of mushrooms contain important phytochemicals with significant potential. This study aimed to investigate the phytochemical prospe...
Disrupted Human-Dog Interbrain Neural Coupling in Autism-Associated Shank3 Mutant Dogs.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) – November 01, 2024
Summary
Dogs and humans can synchronize their brain activity during bonding moments like petting and eye contact. Scientists found that this neural connection grows stronger as relationships deepen. In dogs with Shank3 mutations linked to autism spectrum disorders, this brain synchronization is disrupted. Remarkably, treatment with LSD restored normal brain coupling and social attention in affected dogs.
Abstract
Dogs interact with humans effectively and intimately. However, the neural underpinnings for such interspecies social communication are not understo...